EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Generation and Treatment of a Novel Severe Model of Visceral Gaucher Disease by Genetic Therapy

Amy F Geard, Giulia Massaro iD, Michael P Hughes, Patrick Arbuthnot iD, Simon N Waddington iD, Ahad A Rahim iD

Pharmaceutics · 15.05.2025 · 17 (5) · 650

DOI: 10.3390/pharmaceutics17050650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.05.2025. Verfasst von Amy F Geard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Great Ormond Street Hospital Biomedical Research Centre, UK Medical Research Council, the Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the GBA1 gene. Type 1 Gaucher disease is characterised by substrate accumulation in the visceral organs, which occurs in combination with acute and chronic neurodegeneration that distinguish type 2 and type 3 GD, respectively. We have previously shown the efficacy of neonatal AAV9 gene therapy for treating type 2 GD and aimed to investigate post-symptomatic administration into a model of type 1 disease. Current murine models of type 1 disease are limited in their recapitulation of early onset phenotypic manifestation and thus we aimed to create a novel model of type 1 in which to test the efficacy of adult gene therapy.

Methods

The novel AAV-GD1 model was created through intracerebroventricular injection of AAV9 containing the human GBA1 gene under control of the neuron-specific synapsin promoter (AAV9.hSynI.hGBA1) to the pre-existing acute K14-lnl/lnl model of type 2 GD. Administration of AAV9.hSynI.hGBA1 aimed to restore glucocerebrosidase expression in the brain and extend the lifespan beyond 14 days, allowing the visceral pathology to develop further. The organ pathology was characterised by immunohistochemistry at various time points. Once visceral disease was confirmed, an intravenous injection of AAV9 containing a ubiquitously active CAG promoter driving hGBA1 (AAV9.CAG.hGBA1) was administered to post-symptomatic mice. Animals were aged for 2 and 4 months post-treatment with AAV9.CAG.hGBA1, and immunohistochemistry and enzymatic activity were assessed to investigate therapeutic efficacy.

Results

The AAV-GD1 model displayed visceral pathology in the spleen, lung, and liver from 2 months of age. This allowed us to validate the efficacy of adult gene therapy; intravenous administration of AAV9.CAG.hGBA1 transiently ameliorated the lung pathology and rescued the spleen pathology up to 4 months post-administration.

Conclusions

The creation of the novel AAV-GD1 model with more aggressive visceral pathology presents a unique opportunity for investigation of new therapies to treat type 1 GD. AAV9.CAG.hGBA1 represents a potential therapeutic option for all forms of Gaucher disease.

Schlagwörter

Stichwörter der Autor:innen

AAVGD Type 1Gaucher diseasegene therapymouse model

Autor:innen und Institutionen

  • Department of Pharmacology, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK.
  • Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
  • Maternal & Fetal Medicine, EGA Institute for Women's Health, Faculty of Population Health Sciences, University College London, London WC1E 6HU, UK.

ORCID-Profile: Giulia Massaro, Patrick Arbuthnot, Simon N Waddington, Ahad A Rahim

Förderung

  • NIHR Great Ormond Street Hospital Biomedical Research Centre
  • UK Medical Research Council
  • the Wellcome Trust
  • Institutional Strategic Support Fund/UCL Therapeutic Acceleration Support (TAS)
  • the Sigrid Rausing Trust
  • the Jameel Education Foundation
  • RNID
  • LifeArc

Zitieren

APA

Geard, A. F., Massaro, G., Hughes, M. P., Arbuthnot, P., Waddington, S. N., & Rahim, A. A. (2025). Generation and Treatment of a Novel Severe Model of Visceral Gaucher Disease by Genetic Therapy. Pharmaceutics, 17(5), 650. https://doi.org/10.3390/pharmaceutics17050650

Vancouver

Geard AF, Massaro G, Hughes MP, Arbuthnot P, Waddington SN, Rahim AA. Generation and Treatment of a Novel Severe Model of Visceral Gaucher Disease by Genetic Therapy. Pharmaceutics. 2025;17(5):650. doi:10.3390/pharmaceutics17050650

BibTeX
@article{Geard2025,
  author = {Geard, Amy F and Massaro, Giulia and Hughes, Michael P and Arbuthnot, Patrick and Waddington, Simon N and Rahim, Ahad A},
  title = {Generation and Treatment of a Novel Severe Model of Visceral Gaucher Disease by Genetic Therapy},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {5},
  pages = {650},
  doi = {10.3390/pharmaceutics17050650}
}
Kostenlos starten →